Maze Therapeutics Announces Sizable $150M Growth Offering
Maze Therapeutics priced a $150 million follow-on, selling 5.54 million shares at $23.50 and issuing 0.85 million pre-funded warrants...
Orion’s ODM-212 Trial for Solid Tumours Starts Phase 1b/2
Orion has opened enrollment for TEADCO, a multicenter, open-label Phase 1b/2 basket trial testing its oral pan-TEAD inhibitor ODM-212...
Phase I Trial of PST-611 for Dry AMD Completes Last Visit
PulseSight has completed follow-up on all six patients in its first-in-human PST-611 study for geographic atrophy secondary to dry...
A New Hope: NP137’s Surging Results in Pancreatic Cancer
Phase 1b data from LAPNET-01 in locally advanced pancreatic ductal adenocarcinoma reported median progression-free survival of 10.85 months, median...
New ATH434 Phase 2 Trial Analysis From Alterity Therapeutics
Alterity’s Phase 2 readout for ATH434 in multiple system atrophy showed slower functional decline versus placebo over 52 weeks...
LB-102 Phase 2 Schizophrenia Trial Results in JAMA Psych
In a four-week, placebo-controlled Phase 2 study in acute schizophrenia, LB-102 achieved statistically significant improvement versus placebo at all...
Maze Therapeutics Reveals Tremendous $150 Million Offering
Maze Therapeutics priced a $150 million underwritten public offering, selling 5.54 million shares at $23.50 and issuing pre-funded warrants...
ASCO 2026 Spotlight: ProstAct Phase 3 Late-Breaking Data
Preliminary safety and dosimetry results from the 36-patient lead-in of Telix’s Phase 3 ProstACT Global study will be delivered...
Zymeworks Presents New Phase 1 Data for ZW191 ADC at AACR
ZW191 delivered a confirmed objective response rate of 61% at 6.4–9.6 mg/kg in platinum‑resistant ovarian cancer, with a 57%...
Emerging Daraxonrasib Data for Pancreatic Cancer at AACR
Daraxonrasib delivered a 58% confirmed objective response rate in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (n=40;...